Expeditiontx
San Francisco, US · 4 known investors
Expedition Therapeutics develops oral small-molecule treatments for inflammatory and respiratory diseases, with lead candidate EXPD-101, a once-daily DPP1 inhibitor for chronic obstructive pulmonary disease (COPD). The biotech targets neutrophilic inflammation and is advancing its program into a global Phase 2 trial with expansion potential in bronchiectasis and neutrophilic asthma.
BiotechHealthtech
Investors · 4
Frequently asked questions
- What does Expeditiontx do?
- Expedition Therapeutics develops oral small-molecule treatments for inflammatory and respiratory diseases, with lead candidate EXPD-101, a once-daily DPP1 inhibitor for chronic obstructive pulmonary disease (COPD). The biotech targets neutrophilic inflammation and is advancing its program into a global Phase 2 trial with expansion potential in bronchiectasis and neutrophilic asthma.
- Who are Expeditiontx's investors?
- Expeditiontx's investors include Forbion, Novo Holdings, Sofinnova Ventures, Sanofi Ventures.
- Where is Expeditiontx headquartered?
- Expeditiontx is headquartered in San Francisco, US.